Aditya Anand
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Previous Organizations / Institutes
The organizations / institutes from the scholar's other articles in the past ten years
Research Subjects
Aditya Anand has a total of 39 co-authors. Here are the top co-authors by number of shared publications:
Govindarajan Padmanaban
Department of Biochemistry, Indian Institute of Science, Bangalore, Karnataka, India
4 shared publicationsManjunatha Chandana
Infectious Disease Biology, Institute of Life Sciences, Bhubaneswar, Odisha, India
4 shared publications- Viswanathan Arun Nagaraj
Infectious Disease Biology, Institute of Life Sciences, Bhubaneswar, Odisha, India
4 shared publications Amol Ratnakar Suryawanshi
Infectious Disease Biology, Institute of Life Sciences, Bhubaneswar, India
2 shared publicationsPradeep Mini Vaishalli
Infectious Disease Biology, Institute of Life Sciences, Bhubaneswar, Odisha, India; Regional Centre for Biotechnology, Faridabad, Haryana, India
2 shared publicationsRahul Das
Infectious Disease Biology, Institute of Life Sciences, Bhubaneswar, India
2 shared publications
Latest Publications
- Open Access
Identification of Novel Malaria Antigens Expressed on the Surface of RBCs Infected with Plasmodium falciparum
Background/Objectives: Malaria affects almost half of the world’s population and causes more than 600,000 deaths annually. Young children in malaria-endemic areas have the highest mortality rate because of their immature immune systems. Global efforts to control the disease have had limited success, with two WHO-recommended pre-erythrocytic malaria vaccines showing suboptimal efficacy; no vaccine has yet been approved against the blood stages of the parasite that causes the clinical symptoms of malaria. Therefore, there is an urgent need to identify new vaccine candidates against the parasite’s blood stages to achieve protection against the disease. Methods: Previous studies in our lab identified a few potential vaccine candidates expressed on the surface of malaria-parasite-infected RBCs using sera from disease-resistant children from malaria-endemic regions and a phage-displayed cDNA library generated from P. falciparum. In an innovative approach, we successfully immunized mice using live Plasmodium falciparum-infected red blood cells {Pf-iRBCs (L)}, the membrane fraction of P. falciparum-infected RBCs {Pf-iRBCs (M)}, and live uninfected human red blood cells (hRBCs) in suitable adjuvants. The polyclonal sera produced against Pf-iRBC immunizations were evaluated for specificity and parasite inhibition in vitro and used in a phage display biopanning assay to identify novel antigens on the surface of Pf-iRBCs. Results: Our data indicate that the polyclonal serum produced in BALB/cJ mice, against live Pf-iRBC (L) and their membrane fraction, specifically interacts with surface antigens of parasitic origin on Pf-iRBCs. Additionally, the anti-Pf-iRBC polyclonal serum exhibits significant parasite-killing activity in the in vitro growth inhibition assay (GIA). We have identified both known and novel antigens associated with the Pf-iRBC membrane using phage display cDNA library screening assays. Conclusions: As a proof of concept, our phage display screening identified antigens known to be associated with the Pf-iRBC membrane. Additionally, we identified several unknown Pf-iRBC antigens predicted to be associated with Pf-iRBC membrane (PlasmoDB), suggesting that our approach has the potential to identify novel antigens yet to be evaluated as vaccine candidates against falciparum malaria. In our follow-on studies, we will evaluate the newly identified antigen using an integrated in vitro and in vivo challenge experiment. These studies form the core supporting data for further evaluation of the vaccine potential of novel Pf-iRBC antigens and for follow-on vaccine trials in non-human primates, with an ultimate goal of a malaria vaccine for humans.
Open AccessIdentification of Novel Malaria Antigens Expressed on the Surface of RBCs Infected with Plasmodium falciparum
Background/Objectives: Malaria affects almost half of the world’s population and causes more than 600,000 deaths annually. Young children in malaria-endemic areas have the highest mortality rate because of their immature immune systems. Global efforts to control the disease have had limited success, with two WHO-recommended pre-erythrocytic malaria vaccines showing suboptimal efficacy; no vaccine has yet been approved against the blood stages of the parasite that causes the clinical symptoms of malaria. Therefore, there is an urgent need to identify new vaccine candidates against the parasite’s blood stages to achieve protection against the disease. Methods: Previous studies in our lab identified a few potential vaccine candidates expressed on the surface of malaria-parasite-infected RBCs using sera from disease-resistant children from malaria-endemic regions and a phage-displayed cDNA library generated from P. falciparum. In an innovative approach, we successfully immunized mice using live Plasmodium falciparum-infected red blood cells {Pf-iRBCs (L)}, the membrane fraction of P. falciparum-infected RBCs {Pf-iRBCs (M)}, and live uninfected human red blood cells (hRBCs) in suitable adjuvants. The polyclonal sera produced against Pf-iRBC immunizations were evaluated for specificity and parasite inhibition in vitro and used in a phage display biopanning assay to identify novel antigens on the surface of Pf-iRBCs. Results: Our data indicate that the polyclonal serum produced in BALB/cJ mice, against live Pf-iRBC (L) and their membrane fraction, specifically interacts with surface antigens of parasitic origin on Pf-iRBCs. Additionally, the anti-Pf-iRBC polyclonal serum exhibits significant parasite-killing activity in the in vitro growth inhibition assay (GIA). We have identified both known and novel antigens associated with the Pf-iRBC membrane using phage display cDNA library screening assays. Conclusions: As a proof of concept, our phage display screening identified antigens known to be associated with the Pf-iRBC membrane. Additionally, we identified several unknown Pf-iRBC antigens predicted to be associated with Pf-iRBC membrane (PlasmoDB), suggesting that our approach has the potential to identify novel antigens yet to be evaluated as vaccine candidates against falciparum malaria. In our follow-on studies, we will evaluate the newly identified antigen using an integrated in vitro and in vivo challenge experiment. These studies form the core supporting data for further evaluation of the vaccine potential of novel Pf-iRBC antigens and for follow-on vaccine trials in non-human primates, with an ultimate goal of a malaria vaccine for humans.
- Open Access
- 27 September 2024
- Published by Elsevier in Journal of Biological Chemistry
- Vol. 300 (11) , 107829
Plasmodium berghei HMGB1 controls the host immune responses and splenic clearance by regulating the expression of pir genes
- 27 September 2024
- Published by Elsevier in Journal of Biological Chemistry
- Vol. 300 (11) , 107829
Open AccessPlasmodium berghei HMGB1 controls the host immune responses and splenic clearance by regulating the expression of pir genes
- Open Access
- 14 July 2023
- Published by Springer Nature in Nature Communications
- Vol. 14 (1) , 1-27
Distinct evolution of type I glutamine synthetase in Plasmodium and its species-specific requirement
Malaria parasite lacks canonical pathways for amino acid biosynthesis and depends primarily on hemoglobin degradation and extracellular resources for amino acids. Interestingly, a putative gene for glutamine synthetase (GS) is retained despite glutamine being an abundant amino acid in human and mosquito hosts. Here we show Plasmodium GS has evolved as a unique type I enzyme with distinct structural and regulatory properties to adapt to the asexual niche. Methionine sulfoximine (MSO) and phosphinothricin (PPT) inhibit parasite GS activity. GS is localized to the parasite cytosol and abundantly expressed in all the life cycle stages. Parasite GS displays species-specific requirement in Plasmodium falciparum (Pf) having asparagine-rich proteome. Targeting PfGS affects asparagine levels and inhibits protein synthesis through eIF2α phosphorylation leading to parasite death. Exposure of artemisinin-resistant Pf parasites to MSO and PPT inhibits the emergence of viable parasites upon artemisinin treatment.
- 14 July 2023
- Published by Springer Nature in Nature Communications
- Vol. 14 (1) , 1-27
Open AccessDistinct evolution of type I glutamine synthetase in Plasmodium and its species-specific requirement
Malaria parasite lacks canonical pathways for amino acid biosynthesis and depends primarily on hemoglobin degradation and extracellular resources for amino acids. Interestingly, a putative gene for glutamine synthetase (GS) is retained despite glutamine being an abundant amino acid in human and mosquito hosts. Here we show Plasmodium GS has evolved as a unique type I enzyme with distinct structural and regulatory properties to adapt to the asexual niche. Methionine sulfoximine (MSO) and phosphinothricin (PPT) inhibit parasite GS activity. GS is localized to the parasite cytosol and abundantly expressed in all the life cycle stages. Parasite GS displays species-specific requirement in Plasmodium falciparum (Pf) having asparagine-rich proteome. Targeting PfGS affects asparagine levels and inhibits protein synthesis through eIF2α phosphorylation leading to parasite death. Exposure of artemisinin-resistant Pf parasites to MSO and PPT inhibits the emergence of viable parasites upon artemisinin treatment.
- Open Access
- 13 April 2023
- Published by American Society for Microbiology in Microbiology Spectrum
- Vol. 11 (2) , e0494322
Significance of Plasmodium berghei Amino Acid Transporter 1 in Food Vacuole Functionality and Its Association with Cerebral Pathogenesis
Food vacuoles of the malaria parasite are involved in the degradation of red blood cell hemoglobin. The amino acids derived from hemoglobin degradation support parasite growth, and the heme released is detoxified into hemozoin.
- 13 April 2023
- Published by American Society for Microbiology in Microbiology Spectrum
- Vol. 11 (2) , e0494322
Open AccessSignificance of Plasmodium berghei Amino Acid Transporter 1 in Food Vacuole Functionality and Its Association with Cerebral Pathogenesis
Food vacuoles of the malaria parasite are involved in the degradation of red blood cell hemoglobin. The amino acids derived from hemoglobin degradation support parasite growth, and the heme released is detoxified into hemozoin.
- Open Access
- 12 July 2022
- Published by Springer Nature in Nature Communications
- Vol. 13 (1) , 1-22
Malaria parasite heme biosynthesis promotes and griseofulvin protects against cerebral malaria in mice
Heme-biosynthetic pathway of malaria parasite is dispensable for asexual stages, but essential for mosquito and liver stages. Despite having backup mechanisms to acquire hemoglobin-heme, pathway intermediates and/or enzymes from the host, asexual parasites express heme pathway enzymes and synthesize heme. Here we show heme synthesized in asexual stages promotes cerebral pathogenesis by enhancing hemozoin formation. Hemozoin is a parasite molecule associated with inflammation, aberrant host-immune responses, disease severity and cerebral pathogenesis. The heme pathway knockout parasites synthesize less hemozoin, and mice infected with knockout parasites are protected from cerebral malaria and death due to anemia is delayed. Biosynthetic heme regulates food vacuole integrity and the food vacuoles from knockout parasites are compromised in pH, lipid unsaturation and proteins, essential for hemozoin formation. Targeting parasite heme synthesis by griseofulvin—a FDA-approved antifungal drug, prevents cerebral malaria in mice and provides an adjunct therapeutic option for cerebral and severe malaria.
- 12 July 2022
- Published by Springer Nature in Nature Communications
- Vol. 13 (1) , 1-22
Open AccessMalaria parasite heme biosynthesis promotes and griseofulvin protects against cerebral malaria in mice
Heme-biosynthetic pathway of malaria parasite is dispensable for asexual stages, but essential for mosquito and liver stages. Despite having backup mechanisms to acquire hemoglobin-heme, pathway intermediates and/or enzymes from the host, asexual parasites express heme pathway enzymes and synthesize heme. Here we show heme synthesized in asexual stages promotes cerebral pathogenesis by enhancing hemozoin formation. Hemozoin is a parasite molecule associated with inflammation, aberrant host-immune responses, disease severity and cerebral pathogenesis. The heme pathway knockout parasites synthesize less hemozoin, and mice infected with knockout parasites are protected from cerebral malaria and death due to anemia is delayed. Biosynthetic heme regulates food vacuole integrity and the food vacuoles from knockout parasites are compromised in pH, lipid unsaturation and proteins, essential for hemozoin formation. Targeting parasite heme synthesis by griseofulvin—a FDA-approved antifungal drug, prevents cerebral malaria in mice and provides an adjunct therapeutic option for cerebral and severe malaria.
- 1 February 2016
- Published by Elsevier in Biochemical and Biophysical Research Communications
- Vol. 471 (1) , 205-212
Cobalt chloride-mediated protein kinase Cα (PKCα) phosphorylation induces hypoxia-inducible factor 1α (HIF1α) in the nucleus of gastric cancer cell
- 1 February 2016
- Published by Elsevier in Biochemical and Biophysical Research Communications
- Vol. 471 (1) , 205-212
Cobalt chloride-mediated protein kinase Cα (PKCα) phosphorylation induces hypoxia-inducible factor 1α (HIF1α) in the nucleus of gastric cancer cell